Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Liye Chen has been awarded a Versus Arthritis five-year career development fellowship to identify and validate new T cell therapeutic targets in ankylosing spondylitis (AS).

AS is a painful and progressive form of inflammatory arthritis, affecting around 200,000 people in the UK. The disease causes inflammation in the spine and other joints, leading to pain, stiffness, and fatigue.

Although treatment for AS has greatly improved in the past decade, a definitive cure has not yet been found and many patients suffer persistent symptoms or unacceptable side effects from current therapies.

AS has a strong genetic basis, with over 100 genetic variations linked to the condition. Through bioinformatics integration of genetic data and gene expression profiles of T cells from blood and joint fluid from patients with AS, the innovative programme of research will allow Dr Chen to identify novel T cell regulators in AS which are potential therapeutic targets.

Dr Chen says: “It’s very exciting to be able to look at AS through different lenses and bring such cutting-edge technologies to the table. The integration of multiple datasets (GWAS, eQTL and RNA sequencing of patient-derived T cells) and functional screen of identified genes using disease relevant cellular assays will allow us to identify genes that contribute to AS pathogenesis much faster than currently possible.”

Once the novel AS T cell regulators have been identified and validated in cellular assays, Dr Chen will focus on the most promising and novel regulators for their functional mechanisms and therapeutic potentials.

“I’m very grateful to Versus Arthritis for granting me the opportunity to contribute to such an important field or research, aiding their aims of finding a cure for major forms of arthritis and helping thousands of patients worldwide.” concludes Dr Chen.

Funded by

Versus Arthritis logo

Similar stories

New Botnar Research Institute Director starts today

Professor Jonathan Rees begins his new role as Director of the Botnar Research Institute today, taking over from Professor Andrew Carr.

Patient and public involvement in Rheumatology research – embracing the wave of change

On launching the new OPEN ARMS PPI group in Oxford, Dr. Laura Coates explored the patient and public involvement (PPI) models of three academic centres in the UK to show how it benefits researchers, clinicians, and patients alike.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.